Reference(s)
Click here to return to the Reference Table

Category: Hematopoietic Malignancies
Cancer type: Multiple Myeloma
Descriptor: In vitro studies


Reference Number: 162
Derksen, P. W. et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764-74. (2003).
PubMed link      E-mail link

Reference Number: 167
Borset, M. et al. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 271, 24655-61 (1996).
PubMed link      E-mail link

Reference Number: 168
Derksen, P. W. et al. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99, 1405-10. (2002).
PubMed link      E-mail link

Reference Number: 169
Hjertner, O. et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94, 3883-8 (1999).
PubMed link      E-mail link

Reference Number: 170
Seidel, C. et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96, 3139-46 (2000).
PubMed link      E-mail link

Reference Number: 448
Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 67, 9913-20 (2007)
PubMed link      E-mail link

Reference Number: 514
Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 109, 3024-30 (2007)
PubMed link      E-mail link

Reference Number: 552
Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta. 379, 31-5 (2007)
PubMed link      E-mail link

Reference Number: 814
Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 63, 587-97 (2009)
PubMed link      E-mail link

Reference Number: 815
Zlei M, Egert S, Wider D, Ihorst G, Wäsch R, Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol. 35, 1550-61 (2007)
PubMed link      E-mail link

Reference Number: 956
Que W, Chen J. Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Report. 4,343-9 (2011)
PubMed link      E-mail link

Reference Number: 999
Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem. 286, 6490-9 (2011)
PubMed link      E-mail link

Reference Number: 1351
Rø TB1, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M. HGF and IGF-1 synergize with SDF-1a in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp Hematol. 41, 646-55 (2013)
PubMed link      E-mail link

Reference Number: 1479
Kristensen IB, Pedersen L, Rø TB, Christensen JH, Lyng MB, Rasmussen LM, Ditzel HJ, Børset M, Abildgaard N. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration. Eur J Haematol. 91, 196-200 (2013)
PubMed link      E-mail link